Valeant (VRX), DepoMed (DEPO) Sue Watson (WPI) Over Generic Glumetza
Bloomberg reporting Valent Pharma (NYSE: VRX) and DepoMed (Nasdaq: DEPO) have sued Watson (NYSE: WPI), challenging the company's generic glumetza product.
You May Also Be Interested In
- Puerto Rico Government Opposes Doral Financial Corp's (DRL) Request for Declaratory Judgment
- Spectranetics (SPNC) Receives FDA 510(k) Clearance for ISR Products
- Boston Scientific (BSX) Granted CE Mark For Agent Drug-Coated Balloon
Create E-mail Alert Related CategoriesCorporate News, Litigation
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!